HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lauterbach, H. Articles by Brocker, T. Search for Related Content PubMed PubMed Citation Articles by Lauterbach, H. Articles by Brocker, T. Agricola Articles by Lauterbach, H. Articles by Brocker, T.

Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity

Henning Lauterbach^1,

¹ Institute for Immunology, Ludwig Maximilians University Munich, Goethestrasse 31, 80336 Munich, Germany
² University Claude-Bernard Lyon 1, Centre de Genetique Moleculaire et Cellulaire, Lyon, France
³ University of Ferrara, Department of Experimental and Diagnostic Medicine, Ferrara, Italy

Correspondence
Thomas Brocker
tbrocker{at}med.uni-muenchen.de

Due to the continuous need for new vaccines, viral vaccine vectors have become increasingly attractive. In particular, herpes simplex virus type 1 (HSV-1)-based vectors offer many advantages, such as broad cellular tropism, large DNA-packaging capacity and the induction of pro-inflammatory responses. However, despite promising results obtained with HSV-1-derived vectors, the question of whether pre-existing virus-specific host immunity affects vaccine efficacy remains controversial. For this reason, the influence of pre-existing HSV-1-specific immunity on the immune response induced with a replication-defective, recombinant HSV-1 vaccine was investigated in vivo. It was shown that humoral as well as cellular immune responses against a model antigen encoded by the vaccine were strongly diminished in HSV-1-seropositive mice. This inhibition could be observed in mice infected with wild-type HSV-1 or with a replication-defective vector. Although these data clearly indicate that pre-existing antiviral host immunity impairs the efficacy of HSV-1-derived vaccine vectors, they also show that vaccination under these constraints might still be feasible.

Present address: The Scripps Research Institute, Division of Virology, Department of Neuropharmacology, La Jolla, CA, USA.

This article has been cited by other articles:

				C. Dresch, S. L. Edelmann, P. Marconi, and T. Brocker Lentiviral-Mediated Transcriptional Targeting of Dendritic Cells for Induction of T Cell Tolerance In Vivo J. Immunol., October 1, 2008; 181(7): 4495 - 4506. [Abstract] [Full Text] [PDF]

				M. Werner-Klein, C. Dresch, P. Marconi, and T. Brocker Transcriptional Targeting of B Cells for Induction of Peripheral CD8 T Cell Tolerance J. Immunol., June 15, 2007; 178(12): 7738 - 7746. [Abstract] [Full Text] [PDF]